A panel of pharma representatives and analysts at the 2026 Nordic Life Science Days meeting in Stockholm noted that while licensing deals between US and Chinese biopharma companies hit record highs in 2024, increasing 280% from 2020, there's now an oversupply of mechanistically similar Chinese drugs struggling to find overseas buyers. Additionally, Chinese candidate drug prices have significantly increased, leading to a slowdown in demand, with other Asian regions like India potentially becoming the next market expansion focus.